ArticleAMB Express2026
The gut-liver axis: exploring microbial dysbiosis and specific biomarkers in hepatocellular carcinoma.
Article in AMB Express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hepatocellular carcinoma represents a major global health challenge, with its link to the commensal microbiota being clearly established. However, developing reproducible microbial biomarkers for early-stage hepatocellular carcinoma diagnosis across diverse populations remains challenging. We conducted an integrative analysis of 13 studies, examining 16S rRNA sequencing data from 607 fecal samples and 263 liver tissue samples. Data processing utilized VSEARCH, QIIME, and R packages (vegan, phyloseq, cooccur, random forest), with PICRUSt for functional prediction. Alpha diversity analysis revealed significant differences in liver microbiota but not in gut microbiota between hepatocellular carcinoma patients and non-cancer individuals. Linear Discriminant Analysis Effect Size identified Blautia and Streptococcus as biomarker shared across the gut and liver micro-niches. Based on the internal data, the models constructed using gut and liver microbiome characteristics demonstrated high discriminative ability (gut model AUC = 0.8064; liver model AUC = 0.9645). Mendelian randomization analysis revealed a potential association between Streptococcus and the development of hepatocellular carcinoma. KEGG enrichment analysis further indicated marked functional differences in microbiota, primarily linked to metabolic irregularities, between cancer patients and controls. Therefore, this study reveals unique gut-liver microbial community features in patients with hepatocellular carcinoma, identifies potential cross-site diagnostic biomarkers, and constructs gut and liver predictive model with good performance, providing preliminary evidence for the application of microbial biomarkers in the early diagnosis and screening of hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.